Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Merck
Chinese Patent Office
Teva
QuintilesIMS
US Army
US Department of Justice
Moodys
Colorcon

Generated: May 27, 2018

DrugPatentWatch Database Preview

Septodont Holding Company Profile

« Back to Dashboard

What is the competitive landscape for SEPTODONT HOLDING, and when can generic versions of SEPTODONT HOLDING drugs launch?

SEPTODONT HOLDING has one approved drug.

There are five US patents protecting SEPTODONT HOLDING drugs.

There are thirty patent family members on SEPTODONT HOLDING drugs in twenty countries.

Summary for Septodont Holding
International Patents:30
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Septodont Holding

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes 6,872,390 ➤ Try a Free Trial Y ➤ Try a Free Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes 7,569,230 ➤ Try a Free Trial ➤ Try a Free Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes 7,575,757 ➤ Try a Free Trial Y ➤ Try a Free Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes 6,764,678 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Septodont Holding

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,401 Local anesthetic methods and kits ➤ Try a Free Trial
7,261,889 Local anesthetic methods and kits ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
US Army
Chinese Patent Office
Accenture
McKesson
Deloitte
Moodys
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.